US › Healthcare

Eikon Therapeutics, Inc. Common Stock (EIKN)

US · Healthcare · Biotechnology

$8.60+1.06%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-88.4M

EPS

$-1.63

EPS estimate

$-1.61

EPS came in at -1.63 against a street estimate of -1.61 — a miss of 1.2%.

Key statistics

Market cap

$460.9M

Forward P/E

0.0

P/B

1.10

Book value

$8.62

EPS (TTM)

$-5.34

52-week high

$17.40

52-week low

$7.90

50-day MA

$10.30

200-day MA

$11.07

Analyst view

with an average price target of $24.60.

Shareholding

Insiders

17.38%

Institutions

69.17%

Largest institutional holders

Fund	Stake
FMR Inc	7.08%
BlackRock Inc	6.13%
Foresite Capital Management IV, LLC	3.59%
Merck & Co Inc	3.08%
Foresite Capital Management V, LLC	2.44%
T. Rowe Price Investment Management,Inc.	2.26%
Capital World Investors	2.17%
AllianceBernstein L.P.	1.89%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eikon Therapeutics, Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.